Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
Hidalgo, Universidad Austral de Chile, Chile Mercedes Garca-Roche, Universidad de la Repblica, Uruguay Updates Copyright 2025 Seemann, Kersten, Bhler, Billenkamp, Meyer, Visscher, Huber, Most, Eder, Dnicke and Frahm
Higher cortical porosity leads to lower bone strength and a higher incidence of fragility fractures in this population
Her BA in biochemistry comes from Wellesley College
Topiramate (RR = 1.43